VX-407

Phase 2

Vertex Pharmaceuticals Incorporated (VRTX)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

VRTXPhase 2$114.6B

VX-407 Phase 2 Est. Readout

VX-407• Autosomal Dominant Polycystic Kidney Disease (ADPKD)24

Q3 2027~QConfirmedSTALE

CT.gov

00%

Competitive Landscape

0 competitors in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

View Full Landscape

Drug Information

Target Indication

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Clinical Trial

NCT07161037

Last updated: 12/19/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

VRTX

Vertex Pharmaceuticals Incorporated

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

VX-661 plus ivacaftor combinationPhase 3

Cystic Fibrosis

IVAPhase 3

Cystic Fibrosis

LumacaftorPhase 3

Cystic Fibrosis

ELX/TEZ/IVAPhase 3

Cystic Fibrosis

Tezacaftor/IvacaftorPhase 3

Cystic Fibrosis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts